A BRISC-SHMT Complex Deubiquitinates IFNAR1 and Regulates Interferon Responses  by Zheng, Hui et al.
Cell Reports
ArticleA BRISC-SHMT Complex Deubiquitinates
IFNAR1 and Regulates Interferon Responses
Hui Zheng,1,3 Vibhor Gupta,2,3 Jeffrey Patterson-Fortin,2,3 Sabyasachi Bhattacharya,1,3 Kanstantsin Katlinski,1
Junmin Wu,2 Bentley Varghese,1 Christopher J. Carbone,1 Bernadette Aressy,2 Serge Y. Fuchs,1,*
and Roger A. Greenberg2,*
1Department of Animal Biology and Mari Lowe Comparative Oncology Center, School of Veterinary Medicine, Perelman School of Medicine,
University of Pennsylvania, Philadelphia, PA 19104, USA
2Department of Cancer Biology, Abramson Family Cancer Research Institute, Basser Research Center for BRCA, Perelman School of
Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
3These authors equally contributed to this work
*Correspondence: syfuchs@vet.upenn.edu (S.Y.F.), rogergr@mail.med.upenn.edu (R.A.G.)
http://dx.doi.org/10.1016/j.celrep.2013.08.025
This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-No Derivative Works
License, which permits non-commercial use, distribution, and reproduction in any medium, provided the original author and source are
credited.SUMMARY
Lysine63-linked ubiquitin (K63-Ub) chains represent
a particular ubiquitin topology that mediates protea-
some-independent signaling events. The deubiquiti-
nating enzyme (DUB) BRCC36 segregates into
distinct nuclear and cytoplasmic complexes that
are specific for K63-Ub hydrolysis. RAP80 targets
the five-member nuclear BRCC36 complex to K63-
Ub chains at DNA double-strand breaks. The alterna-
tive four-member BRCC36 containing complex
(BRISC) lacks a known targeting moiety. Here, we
identify serine hydroxymethyltransferase (SHMT) as
a previously unappreciated component that fulfills
this function. SHMT directs BRISC activity at K63-
Ub chains conjugated to the type 1 interferon
(IFN) receptor chain 1 (IFNAR1). BRISC-SHMT2
complexes localize to and deubiquitinate actively
engaged IFNAR1, thus limiting its K63-Ub-mediated
internalization and lysosomal degradation. BRISC-
deficient cells and mice exhibit attenuated re-
sponses to IFN and are protected from IFN-asso-
ciated immunopathology. These studies reveal a
mechanism of DUB regulation and suggest a the-
rapeutic use of BRISC inhibitors for treating patho-
physiological processes driven by elevated IFN
responses.INTRODUCTION
Ubiquitination is a critical modulator of protein activity and func-
tion (Ciechanover and Schwartz, 2004). The status of protein
ubiquitination is determined by counteracting activities of E3
ubiquitin ligases that facilitate ubiquitin conjugation and deubi-
quitinating enzymes (DUBs) that remove the ubiquitin moiety
from proteins (Kimura and Tanaka, 2010; Reyes-Turcu and Wil-180 Cell Reports 5, 180–193, October 17, 2013 ª2013 The Authorskinson, 2009). Accordingly, DUBs have emerged as important
regulators of many physiologic processes including gene
expression, cell division, DNA repair, signal transduction, recep-
tor endocytosis, and trafficking (Amerik and Hochstrasser, 2004;
Clague and Urbe´, 2006).
Whereas an ability to interact with a specific substrate repre-
sents an essential characteristic of numerous E3 ligases, it is
poorly understood how DUBs are targeted to their substrates.
As there are many fewer DUBs (compared to the number of E3
ligases), it is assumed that DUBs are likely to function within
the context of multiprotein complexes and may rely on ancillary
proteins for substrate recognition (Sowa et al., 2009; Ventii and
Wilkinson, 2008).
We have previously reported the nuclear complex DUB con-
taining MERIT40, BRCC45, Abraxas, and BRCC36 that is
capable of disassembling the K63-conjugated polyubiquitin
chain (K63-Ub) upon targeting to DNA damage sites via its inter-
action with the tandem ubiquitin interactionmotif containing pro-
tein RAP80 (Shao et al., 2009a, 2009b; Sobhian et al., 2007). A
related complex appears to represent a major K63-Ub-directed
DUB activity in the cytoplasm (Cooper et al., 2009, 2010; Feng
et al., 2010; Patterson-Fortin et al., 2010). This complex, termed
BRISC (the BRCC36 isopeptidase complex), utilizes KIAA0157/
Abro instead of Abraxas and does not contain RAP80 (Figure 1A).
Both complexes show exquisite specificity for K63-Ub hydroly-
sis, which relies on Zn2+ coordination within the active site of
the JAMM domain of BRCC36 (Cooper et al., 2010; Sobhian
et al., 2007) as well as protein-protein interactions between
BRCC36 and MPN-domain-containing proteins Abraxas and
KIAA0157 for the nuclear RAP80 and cytoplasmic BRISC com-
plexes, respectively (Cooper et al., 2010; Feng et al., 2010;
Patterson-Fortin et al., 2010; Shao et al., 2009b). While both
complexes rely on similar protein interactions for DUB activity,
it is notable that the targeting component of the BRISC has re-
mained elusive, as has a bona fide cytoplasmic substrate of its
DUB activity (Figure 1A).
Here, we report identification of serine hydroxymethyltransfer-
ase (SHMT) as a specific BRISC component that targets the cat-
alytic core of this complex to activated IFNAR1 chains of the type
1 interferon (IFN) receptor. BRISC-SHMT is capable of disas-
sembling the K63-Ub chains from IFNAR1, thus limiting receptor
endocytosis and lysosomal degradation. These activities are
required for receptor-mediated cellular responses to IFN and
its inducers in vitro and in vivo.
RESULTS
Identification of SHMT Species as KIAA0157 Interacting
Partners and Regulators of BRISC Targeting to IFNAR1
To identify proteins that may target BRISC to its substrates, we
utilized a proteomics screen approach in which interacting part-
ners of Abraxas were compared with proteins copurified with the
BRISC-specific KIAA0157 expressed in HeLa S3 cells (Fig-
ure 1B). Examination of the Coomassie-stained gel and tryptic
peptides identified by mass spectrometry revealed common
components of BRCC36, MERIT40, and BRCC45 for both com-
plexes and the exclusive association of RAP80 with the nuclear
Abraxas complex. In addition to the expected BRISC constitu-
ents MERIT40, BRCC45, and BRCC36, we identified serine
hydroxymethyltransferase-2 (SHMT2) as a near stoichiometric
binding partner and specific component of KIAA0157 purifica-
tion (Figures 1B and 1C). Coimmunoprecipitation analysis further
demonstrated that SHMT2 is associated with KIAA0157, but not
with Abraxas (Figure 1D). A related metabolic enzyme SHMT1
was also copurified with KIAA0157, albeit at a lesser peptide
frequency (Figure 1C). Accordingly, KIAA0157 was detected in
immunoprecipitates of endogenous SHMT1 and SHMT2 (Fig-
ure 1E). Consistent these observations, SHMT2 had been re-
ported in a large-scale DUB proteomics screen to interact with
BRCC36 (Sowa et al., 2009). However the functional significance
of this association was not described, nor was it appreciated that
BRCC36 interacts with SHMT2 specifically in the context of the
BRISC complex and not with the RAP80 complex. Our data indi-
cate that SHMT associates with the BRISC complex via the inter-
action with KIAA0157. Mapping of the KIAA0157 that confers
SHMT binding demonstrated that interaction with SHMT2 was
less evident in the KIAA0157mutant lacking the coil-coil domain.
Importantly, the mutant lacking amino acids 215–222 within
KIAA0157 (further termed D215–222) exhibited a decreased
coimmunoprecipitation with SHMT2 while retaining the ability
to interact with BRCC36 (Figures 1F and S1A). SHMT proteins
localize to the mitochondria, cytoplasm, and nucleus. We were
unable to detect any BRISC protein in the mitochondria, sug-
gesting the interaction with SHMT occurs outside of the mito-
chondria (Figure S1B). However, purification of epitope-tagged
KIAA0157 from fractionated HeLa S3 cells revealed the presence
of the BRISC-SHMT complex in both the cytoplasm and nucleus
(Figures S1C and S1D).
SHMT1 and SHMT2 are tetrameric metabolic enzymes
involved in one-carbon metabolism. SHMT1/2 catalyze the
reversible interconversion of serine and tetrahydrofolate to
glycine and methylenetetrahydrofolate. This reaction generates
single-carbon units for purine, thymidine, and methionine
biosynthesis. Wewere unable to detect a SHMT catalytic activity
associated with BRISC in KIAA0157 purifications, while similar
amounts of the enzyme purified by SHMT2 immunoprecipitates
demonstrated robust exchange of tritium from glycine to H2O asCmeasured by an isotopic assay with known specificity for SHMT
activity (Scheer et al., 2005) (Figures 1G and 1H). These observa-
tions are consistent with SHMT playing a structural function in
the context of its association with BRISC, rather than a catalytic
role in conjunction with BRISC DUB activity.
The preceding data suggest that SHMT proteins may function
analogously to RAP80 in the BRISC DUB complex, potentially
targeting BRISC to K63-linked polyubiquitin chains conjugated
to substrate proteins. Intriguingly, SHMT2 proteins were also
pulled down together with double coimmunoprecipitation with
FLAG-tagged IFNAR1 chain and hemagglutinin (HA)-tagged IF-
NAR2 chain of the type 1 IFN receptor (Figures S2A and S2B).
This receptor is rapidly downregulated in response to ligand
and numerous nonligand stimuli (Fuchs, 2013; Huangfu and
Fuchs, 2010) that trigger robust phosphorylation-dependent
ubiquitination of the IFNAR1 chain facilitated by the SCF-
b-Trcp E3 ubiquitin ligase (Kumar et al., 2003, 2004). Importantly,
both the presence of K63-Ub on IFNAR1 and the role of these
ubiquitin chain topologies in IFNAR1 endocytosis and degrada-
tion have been demonstrated (Fuchs, 2012; Kumar et al., 2007).
Coimmunoprecipitation experiments using either endogenous
(Figure 2A) or FLAG-tagged recombinant (Figure S2C) IFNAR1
corroborated its ability to interact with SHMT2 in naive cells
and demonstrated that this interaction is further increased by
treatment of cells with IFN. In addition, increased association be-
tween endogenous SHMT2 and FLAG-KIAA0157 was found in
immunoprecipitates from the ligand-treated cells (Figure 2B),
while the D215–222 protein failed to show such increases (Fig-
ure 2B). This result suggests that IFNAR1 engagement by ligand
promotes a ternary complex with BRISC and SHMT2.
Proximity ligation assay analysis using the Duolink approach
was employed to visualize colocalization of BRISC, SHMT2,
and IFNAR1 in cells given the broad subcellular localization of
SHMT and BRISC using standard immunofluorescence tech-
niques. Duolink analysis demonstrated that IFNAR1 is capable
of interacting with KIAA0157 and SHMT2 in intact cells. Impor-
tantly, knockdown of both SHMT1 and SHMT2 dramatically
decreased the latter interaction, and similarly KIAA0157 knock-
down decreased interaction between SHMT2 and IFNAR1 (Fig-
ures 2C and 2D), consistent with codependency of BRISC and
SHMT for IFNAR1 targeting. Consistent with protein purification
studies (Figures S1C and S1D), Duolink signal for interactions
among all species was observed in both the cytoplasm and the
nucleus (Figure S2D).
We next sought to delineate the mechanism underlying an in-
crease in this recruitment in the IFN-treated cells. Treatment of
cells with ligand was shown to stimulate the ubiquitination of
endogenous IFNAR1 by increasing the serine phosphorylation
of its degron (including S535) that enables the recruitment of
b-Trcp2 (also termed HOS or FBXW11; Kumar et al., 2003,
2004). In addition, overexpression of recombinant IFNAR1
and other inducers of unfolded protein responses can trigger
ligand-independent IFNAR1 phosphorylation and ubiquitination
(Fuchs, 2013; Liu et al., 2009). Importantly, the knockdown using
small hairpin RNA (shRNA) targeted to both b-Trcp1 and b-Trcp2
noticeably decreased K63-Ub conjugation to the endogenous
IFNAR1 as well as decreased the recruitment of SHMT2 to this
receptor (Figure 2E). Moreover, mutant IFNAR1S535A that isell Reports 5, 180–193, October 17, 2013 ª2013 The Authors 181
Figure 1. Identification of SHMT Species as a Fifth Component of the BRISC Complex
(A) Schematic comparison of the nuclear RAP80 complex that directs BRCC36-mediated DUB activity at K63-Ub chains formed at DNA damage sites with the
cytoplasmic BRISC complex whose substrates and targeting components remain unknown.
(B) Proteins copurified with either FLAG-HA-Abraxas (eAbraxas) or KIAA0157 (eKIAA0157) were separated by SDS-PAGE and stained using Coomassie
brilliant blue.
(C) Tabular display of the number of tryptic peptides from each of the indicated proteins that copurified with eKIAA0157.
(D) FLAG immunoprecipitation (IP) reveals association of SHMT2 with KIAA0157, but not Abraxas.
(E) KIAA0157 was detected by immunoblot following IP of endogenous SHMT1 or SHMT2.
(F) 293T cells transiently expressing wild and mutant FLAG-tagged versions of KIAA0157 were lysed and used for FLAG-IP. Coimmmunoprecipitated proteins
were detected using different antibodies as indicated.
(legend continued on next page)
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incapable of binding b-Trcp and thus exhibits greater stability
and signaling (Kumar et al., 2003) demonstrated negligible inter-
action with SHMT2 in either untreated or treated cells (Figure 2F).
Collectively, the data suggest that ubiquitination of IFNAR1 stim-
ulates the recruitment of SHMT2 by direct and/or indirect
mechanisms.
The BRISC-SHMT Complex Regulates Ubiquitination,
Endocytosis, and Proteolytic Turnover of IFNAR1
Incubation of recombinant BRISC with IFNAR1 robustly decon-
jugated the K63-linked chain from this receptor (Figure S3A),
raising the possibility IFNAR1 is a BRISC substrate. Indeed,
knockdown of either KIAA0157 or SHMT2 (Figure 3B) or of
BRCC36 (Figure 3C) noticeably increased the extent of ligand-
induced K63-linked ubiquitination of IFNAR1. This outcome
might result from indirect regulatory effects of BRISC compo-
nents on either protein kinases that phosphorylate IFNAR1 to
enable the recruitment of b-Trcp or on the activity of the SCF-
b-Trcp E3 ubiquitin ligase itself. However, we considered these
possibilities unlikely because knockdown of BRISC components
affected neither IFNAR1 phosphorylation on Ser535 (Figure 3B)
nor the K48-linked chains on IFNAR1 (Figure 3C), revealing spec-
ificity for DUB activity on IFNAR1 conjugated to K63-Ub.
In line with this possibility, HeLa cells stably overexpress-
ing wild-type BRCC36, but not its enzymatically inactive
BRCC36QSQ mutant (described in detail in Shao et al., 2009b;
Sobhian et al., 2007), robustly decreased the K63-linked ubiqui-
tination of IFNAR1 (Figure S3C). IFNAR1 ubiquitination was also
noticeably increased in cells expressing KIAA0157 D215–222
protein, suggesting SHMT2-dependent BRISC targeting is
required to deubiquitinate IFNAR1 (Figure 3D). Finally, to obtain
unequivocal genetic data on the role of BRISC in IFNAR1 ubiqui-
tination, we have generated KIAA0157 knockout mice by delet-
ing exons 6 and 7 of the murine KIAA0157 locus (Figure S4).
Thesemicewere viable and fertile and harbored an intact nuclear
RAP80 complex (data not shown), but no detectable KIAA0157
protein. In embryonic fibroblasts (MEFs) obtained from
KIAA0157/ mice, we observed a much greater induction of
K63-Ub on IFNAR1 compared to cells from wild-type animals
(Figure 3E). Together, these data strongly suggest that BRISC
is recruited to IFNAR1 via interaction with SHMT and that this
complex is a key regulator of receptor K63-ubiquitination.
Ubiquitination of signaling receptors localized at the cell sur-
face often regulates endocytosis of these proteins (Clague and
Urbe´, 2006; Haglund and Dikic, 2012). K63-Ub chains were
shown to contribute to the stimulation of IFNAR1 endocytosis
and acceleration of the proteolytic turnover of this receptor in
the lysosomes (Kumar et al., 2007). Consistent with the pro-
posed role of BRISC in regulating IFNAR1 ubiquitination (Fig-
ure 3), we observed that knockdown of either SHMT1/2 or
KIAA0157 (but not of Abraxas) increased the internalization
rate of IFNAR1 in the IFN-treated cells (Figure 4A). To determine
whether BRISC regulates the turnover of IFNAR1, we conducted(G) Immunoblot displaying similar amounts of SHMT2 from IP of either FLAG-HA
activity was assayed from these immunoprecipitates (IPs).
(H) SHMT activity was observed in IPs of SHMT, but not KIAA0157. Similar resu
See also Figures S1 and S2.
Ccycloheximide chase analyses on endogenous IFNAR1 inmouse
and human cells treated with species-specific IFN (human IFNa
or mouse IFNb). Degradation of human IFNAR1 was accelerated
upon knockdown of either BRCC36 or KIAA0157 (Figure 4B)
or SHMT2 (Figure 4C). Furthermore, a greater rate of mouse
IFNAR1 turnover was seen in KIAA0157 knockout MEFs (Fig-
ure 4D). These results suggest that BRISC-SHMT complex
counteracts ubiquitination of IFNAR1 and, accordingly, functions
to reduce the rate of receptor internalization and degradation.
BRISC-SHMT Controls Cellular IFNAR1-Mediated
Signaling and Cellular Responses to IFN and Bacterial
Lipopolysaccharide
Given that themaintenance of IFNAR1 levels is critical for cellular
responses to IFN (Fuchs, 2013), it is plausible that themagnitude
and/or duration of cellular responses to IFN would be attenuated
by impaired function of BRISC or its inadequate recruitment
to IFNAR1. Consistent with this possibility, either activation
of STAT1 or induction of PKR by IFN was noticeably weaker
in KIAA0157 knockout MEFs compared to their wild-type
counterparts or where the KIAA0157-D215–222 mutant was
overexpressed (Figures 5A–5C). A similar attenuating effect on
induction of STAT1 phosphorylation or induction of ISG15 and
PKR was seen in primary human fibroblasts or in HeLa cells
where either SHMT2 or BRCC36 or KIAA0157 were knocked
down (Figure 5D). Furthermore, the antiproliferative effects of
IFN were less pronounced in KIAA0157/MEFs and derivatives
of these cells reconstituted with KIAA0157-D215–222 mutant
(compared to their wild-type counterparts or knockout MEFs
where wild-type KIAA0157 was re-expressed; Figure 5E). In
agreement, IFN afforded a somewhat lesser protection from
infection with vesicular stomatitis virus in KIAA0157 knockout
MEFs (Figures 5F and S5), reinforcing the notion that BRISC-
SHMT activities are required for the full extent of IFN signaling
and its biological effects.
When cells respond to exogenously added IFN, both ubiquiti-
nation of IFNAR1 (counteracted by BRISC-SHMT) and JAK-
STAT signaling are activated concurrently. Accordingly, the role
of BRISC-SHMT in regulating IFN signaling might be even more
pronounced within the ligand-independent pathway of IFNAR1
ubiquitination (Fuchs, 2013; Liu et al., 2008, 2009). As bacterial
lipopolysaccharide (LPS) induces IFNAR1 ubiquitination and
downregulation evenprior to stimulating the TLR4-mediated pro-
duction of endogenous IFN (Qian et al., 2011), we examined the
role of BRISC within the context of cellular responses to LPS.
Consistent with the role of BRISC in regulating IFNAR1 endocy-
tosis (Figure 4A), we observed a greater extent of IFNAR1 down-
regulation on the surface of peripheral blood leukocytes from
LPS-treated KIAA0157 null mice compared to those from wild-
type animals (Figure 6A). Given a key role of weak IFNAR1-medi-
ated tonic signaling in subsequent induction of type 1 IFN ligands
(Gough et al., 2012; Taniguchi and Takaoka, 2001), it is antici-
pated that lesser induction of these genes would be observed-KIAA0157 or endogenous SHMT2 from HeLa and 293T cells. SHMT catalytic
lts were observed in both cell lines.
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Figure 2. Interferon Stimulation Enhances BRISC-SHMT2 Interaction and Association with IFNAR1
(A) 293T cells were treated with IFNa for the indicated times. IFNAR1 was immunoprecipitated and then SHMT2 and IFNAR1 were detected by immunoblotting
using the indicated antibodies. WCL, whole cell lysates.
(B) Cells expressingwild-type (WT) andD215–222mutant KIAA0157were treatedwith or without IFNa for 15min. FLAG-IPwas performed and copurified proteins
were detected using the indicated antibodies.
(C) Proximity ligation assay showing interaction between KIAA0157 or SHMT2 and IFNAR1 (proximity foci). U2OS cells with stable expression of FLAG-HA-
KIAA0157were transfectedwith the indicated small interfering RNAs (siRNAs) and interaction between KIAA0157 or SHMT2 and IFNAR1was studied using rabbit
IFNAR1 and mouse anti-HA.
(legend continued on next page)
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Figure 3. The BRISC-SHMT Complex Regu-
lates K63-Linked Ubiquitination of IFNAR1
(A) 2fTGHcellswith stable knockdownofKIAA0157
or SHMT2 were incubated with or without IFNa as
indicated. IFNAR1 was immunoprecipitated from
cell lysates and K63-Ub, pS535, and IFNAR1 were
detected using the indicated antibodies.
(B) 2fTGH cells with stable knockdown of BRCC36
were treated as in B. IFNAR1 was immunopre-
cipitated from cell lysates and K63-Ub, pS535,
and IFNAR1 were detected using the indicated
antibodies.
(C) FLAG-IFNAR1 was immunoprecipitated from
293T cells and immunoblot was performed using
antibodies specific to K48-Ub chains as indicated.
(D) K63-Ub modification and degron phosphory-
lation of endogenous IFNAR1 in cells expressing
wild-type KIAA0157 or its D215–222 mutant.
(E) MEFs from wild-type or KIAA0157 null mice
were treated with or without mIFNb for 30 min.
IFNAR1 was immunoprecipitated from cell lysates
and K63-Ub, pS526 (corresponding to human
pS535), and IFNAR1 were detected using the
indicated antibodies.
See also Figures S3 and S4.in the BRISC-deficient mice. Indeed, LPS-triggered induction of
messenger RNA (mRNA) for IFNb (but not IFNa4) was signifi-
cantly attenuated in leukocytes from KIAA0157/ mice (Fig-
ure 6B). Similarly, an attenuated induction of IFNb mRNA was
seen in LPS-treated MEFs from these mice (data not shown).
This combination of accelerated IFNAR1 downregulation and
decreased IFN production would likely limit the extent of cellular
responses to LPS in these animals.(D) Quantification of foci from (A). All data and error bars represent mean ± SEM from at least three independ
sample. p values were calculated using the Student’s t test.
(E) 293T cells were transfected with shRNAs against GFP or b-Trcp (BTR). Cells were treated with IFNa for the
and SHMT2, K63-Ub, pS535, and IFNAR1were detected by immunoblotting using the indicated antibodies. W
immunoblotting.
(F) 293T cells were transfected with FLAG-IFNAR1 WT or FLAG-IFNAR1 S535A. Cells were treated with
immunoprecipitated and SHMT2, K63-Ub, pS535 and FLAG-IFNAR1 were detected by immunoblotting usin
See also Figures S1 and S2.
Cell Reports 5, 180–193,Consistent with this hypothesis,
strongly reduced STAT1 phosphorylation
and ISG15 protein levels were observed
in KIAA0157/ cells or in primary human
fibroblasts following KIAA0157 knock-
down in comparison to WT and control
knockdown cells, respectively (Figures
6C, 6D, and S6A). In addition,
KIAA0157/ MEFs demonstrated resis-
tance to the cytotoxic effect following
treatment with LPS and cycloheximide,
whereas reconstitution with wild-type,
but not KIAA0157-D215–222, restored
sensitivity to LPS (Figure 6E). These ex-
periments implicate BRISC as an impor-
tant regulator of cellular responses toLPS-induced endogenous IFN and suggest that this regulation
specifically depends on loss of interaction with SHMT2.
Besides inducing production of IFN, LPS may elicit IFN-inde-
pendent effects on cells including induction of inflammatory
cytokines such as interleukin 1b (IL1b). Levels of functional
secreted IL1b protein are determined by transcriptional regula-
tion of mRNA of IL1b precursor as well as by its subsequent
processing by caspase-1 (Andrei et al., 1999; Gabay et al.,ent experiments that included at least 100 cells per
indicated times. IFNAR1 was immunoprecipitated
CLwas used for detection of b-Trcp and b-actin by
IFNa for the indicated times. FLAG-IFNAR1 was
g the indicated antibodies.
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Figure 4. BRISC-SHMT Regulates Endocytosis, Proteolytic Turnover, and Abundance of IFNAR1
(A) Internalization rate of endogenous IFNAR1 in IFN-stimulated 293T cells that had been transfected the indicated siRNAs.
(B) 2fTGH cells with stable knockdown of BRCC36 or KIAA0157 were treated with IFNa together with CHX (20 mg/ml) for the indicated times. IFNAR1 was
immunoprecipitated and detected using specific antibodies. b-actin, KIAA0157, and BRCC36 were detected from WCL using the indicated antibodies.
(C) 2fTGH cells with stable knockdown of SHMT2 were treated with IFNa together with CHX (20 mg/ml) for the indicated times. IFNAR1 was immunoprecipitated
and detected using specific antibodies. b-actin and SHMT2 were detected from WCL using the indicated antibodies.
(D) MEFs from wild-type or KIAA0157 knockout mice were treated with mouse IFNb together with CHX (20 mg/ml) for the indicated times. mIFNAR1 was
immunoprecipitated and detected using specific antibodies. b-actin and MERIT40 were detected from WCL using the indicated antibodies.2010; Watkins et al., 1999) that can be activated by multiprotein
complexes termed inflammasomes (Schroder and Tschopp,
2010). Remarkably, a recent report demonstrated that pharma-
cologic administration of the nonspecific DUB inhibitor G5 sup-
pressed the LPS-induced activation of caspase-1 and ensuing
activation of the inflammasome-dependent production of IL1b.
Based on these findings and knockdown experiments, it
was suggested that BRISC-mediated deubiquitination of the
NLRP3 inflammasome in response to LPS might be an event
required for caspase-1 activation (Py et al., 2013). To determine
if reduced inflammasome activation could complement the
effects elicited upon IFNAR1within the context of LPS response,
we monitored caspase-1 cleavage products in primary bone
marrow macrophages derived from KIAA0157/ and wild-
type mice (n = 6 for each genotype). Remarkably, caspase-1
activation was, at the very least, not impaired in LPS-treated
KIAA0157/ macrophages (Figure S6B), indicating that BRISC
inhibition probably does not account for the pharmacologic
effects of G5 on inflammasome activation. A decreased induc-
tion of IL1b mRNA observed in BRISC knockout blood leuko-
cytes (Figure 6B) is likely to contribute to a somewhat lower level
of IL1b (and other proinflammatory cytokines) detected in
plasma from KIAA0157/ mice (Figure S6C).186 Cell Reports 5, 180–193, October 17, 2013 ª2013 The AuthorsImportantly, while protecting from viral infections, IFN also
plays a key role in mechanisms of immunopathology (Trinchieri,
2010). For example, in the model of septic shock induced by
intraperitoneal LPS injections in vivo, IFNAR1 expression was
required for mortality over a 5-day period (Karaghiosoff et al.,
2003). To determine the in vivo role of BRISC in regulating these
responses we injected cohorts of female littermate control
KIAA0157+/+ or KIAA0157/ mice with LPS and monitored
IFNAR1 signaling, receptor levels, and mortality. As expected
from a combination of lower ligand production and lesser recep-
tor levels (Figure 6), BRISC deficiency resulted in strong attenu-
ation of IFN responses in vivo as seen from reductions in LPS
induced STAT1 phosphorylation and ISG15 induction (Figures
7A and S7). Moreover, KIAA0157/ mice that received LPS
injections exhibited a markedly decreased severity of LPS-
induced lung injury, manifested in lesser erythrocyte extravasa-
tion, leukocytic infiltration of the interstitial and alveolar spaces,
edema, and alveolar distortion (Figure 7B). Accordingly, consis-
tent with the importance of IFNAR1 levels for LPS toxicity (Kara-
ghiosoff et al., 2003) and the requirement for KIAA0157 for
IFNAR1 levels maintenance (Figures 4 and 6A), BRISC-deficient
animals displayed significantly reduced mortality (Figure 7C).
Collectively, these results are consistent with SHMT-BRISC
Figure 5. BRISC-SHMT Interaction Promotes Responses to IFN
(A) KIAA0157+/+ or KIAA0157/MEFs were treated with IFNb for the indicated times. STAT1 Tyr701 phosphorylation and total STAT1 levels were detected from
cell lysates using specific antibodies.
(B) MEFs of each genotype were either continuously exposed to mouse IFNb for 24 hr or pulsed with IFN for 2 hr and then incubated without IFN for total of 24 hr.
Levels of PKR and b-actin were detected from whole cell lysates using the indicated antibodies.
(C) 2fTGH cells stably expressing WT KIAA0157 or mutant KIAA0157-DM1 were treated with human FNa and analyzed as in (B).
(D) 2fTGH cells with stable knockdown of SHMT2 or KIAA0157 or BRCC36 were pulse-treated with IFNa for 2 hr and then IFNawas removed and cells harvested
24 hr after initial treatment. Alternatively, cells were treated with IFNa continuously for 24 hr. Whole cell lysates were used for detection of PKR and b-actin as
indicated.
(E) KIAA0157+/+, KIAA0157/, and reconstituted null MEFs were treated with or without mIFNb (200 U/ml) for 48 hr and cell viability was analyzed by Trypan blue
exclusion assay.
(F) Viral titers were measured in VSV infected KIAA0157+/+ and KIAA0157/ MEFs from two independent experiments (each in triplicate).
See also Figure S5.targeting to IFNAR1 as a contributing factor to mortality in
response to LPS.
DISCUSSION
It has become increasingly clear that many DUBs utilize protein-
protein interactions to affect enzymatic activity, cellular localiza-
tion, and access to substrates (Ventii and Wilkinson, 2008). ForCexample, USP1’s interaction with UAF1 is necessary for DUB
activity in vitro and deubiquitination of cellular substrates
PCNA and FANCD2 (Cohn et al., 2007; Huang et al., 2006; Nij-
man et al., 2005). Notably, several JAMM domain DUBs
including Poh1 and BRCC36 fail to display proteolytic activity
as a single polypeptide, instead necessitating additional pro-
tein-protein interactions (Cooper et al., 2010; Feng et al., 2010;
Patterson-Fortin et al., 2010; Verma et al., 2002; Yao and Cohen,ell Reports 5, 180–193, October 17, 2013 ª2013 The Authors 187
Figure 6. BRISC Deficiency Confers Severely Reduced Interferon Signaling in Response to LPS
(A) Fluorescence-activated cell sorting analysis of cell surface IFNAR1 levels in peripheral blood leukocytes (PBL) isolated from KIAA0157+/+ and KIAA0157/
mice (n = 3 for each genotype) 3 hr after LPS treatment.
(B) Real time RT-PCR analysis of the indicated cytokine mRNA levels in PBL from KIAA0157+/+ and KIAA0157/ mice (n = 4 for each genotype) in response to
LPS treatment.
(C) KIAA0157+/+ and KIAA0157/ MEFs were treated with or without 1 mg/ml of LPS for 20 hr and cell lysates were analyzed by immunoblotting as indicated.
(D) KIAA0157+/+ and KIAA0157/MEFs were treated with or without 1 mg/ml of LPS for indicated periods of time, and levels activated STAT1 (pSTAT-Y701) and
other proteins were analyzed in WCL using the indicated antibodies.
(E) KIAA0157+/+, KIAA0157/, and reconstituted KIAA0157/MEFs were treated with or without LPS (10 ng/ml) and 10 mg/ml CHX for 24 hr. Cells viability was
analyzed by Trypan blue exclusion assay.
See also Figure S6.
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Figure 7. KIAA0157/ Mice Display Reduced Interferon Signaling, Tissue Damage, and Mortality in Response to LPS In Vivo
(A) KIAA0157+/+ and KIAA0157/ mice were injected with the indicated amount of LPS for different time periods and lung and liver were harvested for protein
analysis by western blot.
(B) Wild-type and KIAA0157 null mice were injected with 10.5 mg/kg LPS for 4–5 days and their lungs were harvested, fixed, and then stained with hematoxylin
and eosin (H&E).
(C) Kaplan-Meier survival curves were generated after injecting 10.5 mg/kg LPS in wild-type and KIAA0157 null mice.
(D) Model depicting IFN-inducible SHMT-BRISC assembly and deubiquitination activity on IFNAR1 and possibly other substrates (X).
See also Figure S7.2002). BRCC36 requires interaction with KIAA0157 for minimal
DUB activity in vitro while the nuclear RAP80 complex requires
the combined association with Abraxas and BRCC45 (Cooper
et al., 2010; Feng et al., 2010; Patterson-Fortin et al., 2010).
RAP80 provides a recognition element for nuclear BRCC36
through its tandem ubiquitin interaction motifs, which show
specificity for K63-Ub binding (Sobhian et al., 2007). This interac-
tion is essential for BRCC36 DNA damage site targeting and
deubiquitination of K63-Ub substrates gH2AX and RAP80 (Pat-
terson-Fortin et al., 2010; Shao et al., 2009a).
As opposed to the nuclear complex, mechanisms of substrate
targeting for the cytoplasmic BRISC had not been previously
appreciated. This study provides insights into the regulation ofCBRISC-dependent K63-Ub deubiquitination (Figure 7D). A
cytokine-inducible interaction between BRISC and SHMT is
necessary for efficient IFNAR1 deubiquitination and contributes
to its subcellular localization. This interaction is important for
restricting receptor degradation and, hence, for maximal
responses to IFN at the cellular and organismal levels. The
data suggest both similarities to and differences from nuclear
BRCC36 regulation. Both the BRISC and RAP80 complexes
respond to signal-induced ubiquitination at the plasma mem-
brane and DNA double-strand breaks, respectively. However,
the nuclear complex relies on a constitutive interaction with a
canonical ubiquitin binding protein, RAP80, while the BRISC
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IFNAR1-activated association between SHMT2 and BRISC.
While phosphorylation-dependent IFNAR1 ubiquitination by
b-Trcp was required for this association, it is not clear if SHMT’s
interaction with the BRISC increases affinity for K63-Ub or if
another associated recognition event is responsible for localiza-
tion. Notwithstanding, the utilization of ancillary recognition
components may represent a general mechanism by which the
DUB complexes are targeted to their substrates. Given that
BRISC represents a major K63-Ub-specific DUB activity in the
cytoplasm (Cooper et al., 2009), it is likely that it is also targeted
to many other substrates (besides IFNAR1) through either SHMT
or functionally similar moieties (Figure 7D). Furthermore, deubi-
quitination of these yet-to-be-identified substrates could also
contribute to in vivo responses to LPS and other stimuli. The
identification of additional BRISC-SHMT substrates and the
biochemical mechanisms of their recognition represent inter-
esting topics for future investigation.
A second feature of this study is its potential medical signifi-
cance. Elevated IFNAR1 signaling has been implicated in a vari-
ety of disease states, including Gram-negative endotoxic shock
and autoimmune conditions such as rheumatoid arthritis and
systemic lupus erythematosis. Mouse models of the latter
demonstrate a remarkable attenuation of syndrome severity
upon inactivation of IFNAR1 (Agrawal et al., 2009; Nacionales
et al., 2007). Accordingly, means to limit this signaling (such as
neutralizing antibodies) might benefit this group of patients
(Stewart, 2003). Indeed, human trials using antibodies against
IFN to treat systemic lupus erythematosis have entered late-
stage clinical trials with evidence of efficacy (McBride et al.,
2012).
Data presented here argue that inhibition of BRISC DUB activ-
ity may represent a promising strategy for treating pathologic
conditions that arise as a result of elevated IFNAR1 signals.
KIAA0157/ mice have ablated BRISC activity while sparing
the nuclear RAP80 complex. Thesemice display no overt pheno-
type in the absence of stress, suggesting that BRISC inhibition
may be well tolerated. However, we were able to document
impaired IFNAR1-dependent signals in response to IFN and
LPS in knockout cells and mice. More importantly, KIAA0157/
mice tolerated LPS better than their wild-type counterparts.
While rapid downregulation of IFNAR1 and ensuing weakening
of tonic signaling toward expression and production of IFN
ligands is likely to represent a major mechanism by which
BRISC-deficient mice are desensitized to LPS, the contribution
of other putative targets of BRISC cannot be excluded
(Figure 7D).
Importantly, BRISC inhibition attenuates, but does not elimi-
nate, IFNAR1 levels and IFNAR1-mediated signaling (Figure 5).
Given that the establishment of an antiviral state requires much
lower receptor density than the antiproliferative/survival effects
of IFN (reviewed in Piehler et al., 2012), it is not surprising that
the antiviral phenotype of BRISC deficiency is fairly subtle
(Figures 5F and S5). Importantly, the medical benefits of BRISC
inhibition is that partial IFNAR1 destabilization should prevent
immunopathology without substantially compromising antiviral
defenses. Accordingly, targeting BRISC may conceivably help
to ameliorate diseases that have elevated IFNAR1 responses,
while not producing unwanted susceptibility to viral pathogens.190 Cell Reports 5, 180–193, October 17, 2013 ª2013 The AuthorsThe data presented in this study suggest the need for developing
potent and selective BRISC inhibitors to test this hypothesis
in vivo.
EXPERIMENTAL PROCEDURES
Reagents
The following antibodies and other reagents were purchased from the
following commercial sources: Sigma-Aldrich (M2 FLAG, cycloheximide,
anti-SHMT2, tetrahydrofolate), BioLegend (mouse immunoglobulin G 1
[IgG1]-biotin), eBioscience (Streptavidin-PE, 12-4317, ELISA kit for detection
of IL1b), Cell Signaling (anti-pSTAT1, STAT1, tubulin, ISG15), Leinco Technol-
ogies (anti-mIFNAR1), PBL Laboratories (mouse and human IFN), Santa Cruz
(PKR, caspase-1, STAT-1), Millipore (K63-Ub, K48-Ub), and LS Biosciences
(anti-KIAA0157). In-house-produced purified antibodies were also used for
detecting BRCC36 and MERIT40 and immunoprecipitating Abraxas,
KIAA0157, and SHMT2 proteins. Antibodies against phosphoSer535-IFNAR1
were previously described (Kumar et al., 2004). 3H glycine and western lighting
ECL substrate were procured from Perkin Elmer and Bradford reagent, and
AG-50 X8 ion exchange matrix were from Bio-Rad. The Duolink assay kit
was purchased from Olink Bioscience. The 4%–12% Bis-Tris gel, Trizol, Lip-
ofectamine 2000, Lipofectamine RNAi, cell culture media, and other materials
for tissue culture were purchased from Invitrogen.
Cell and Tissue Lysis, Immunoprecipitation, and Immunoblotting
Cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) with 10%
fetal bovine serum (FBS). Cell lysis was performed in NETN-150 buffer (20 mM
Tris [pH 7.4], 150 mM NaCl, 0.5 mM EDTA, 0.5% NP40 with 5mM 2-mercap-
toethanol and 1 mM phenylmethanesulfonylfluoride [PMSF]). Tissue samples
from mice were snap frozen in liquid nitrogen, crushed in mortar pestle, and
incubated with NETN-150 buffer on ice for 20 min and then sonicated and
spun down at maximum speed. Supernatant was used further for protein esti-
mation and immunoblot. For immunoprecipitation, FLAGM2 agarose beads or
antibody-coated protein A/G (according to experiment) agarose was incu-
bated for 1–2 hr in cell lysate and washed three times with NETN150 buffer.
Immunoprecipitated material was eluted using either FLAG peptide or glycine
and separated on 4%–12% Bis-Tris gel.
For assessment of IFNAR1 ubiquitination in cells, endogenous or FLAG-
tagged recombinant IFNAR1 species were immunoprecipitated with a corre-
sponding antibody. The samples were washed three times with 50 mM Tris
(pH 7.4), 5% glycerol, and 1M NaCl and one time with 50 mM Tris (pH 7.4),
5% glycerol, and 150 mM NaCl and then eluted with SDS-containing Laemmli
buffer. Resulting samples were separated by SDS-PAGE and analyzed by
immunoblotting using the chain-specific anti-K63-Ub or K48-Ub antibodies
(Millipore).
Proximity Ligation Assay and Immunofluorescence
A modified form of proximity ligation assay (Duolink assay, Olink Bioscience)
was performed according to the vendor’s recommendations. U2OS cells
with either stable or transient expression of FLAG-HA proteins were grown
on coverslips and fixed using 3% paraformaldehyde/2% sucrose solution.
Fixed cells were washed twice with PBS and permeabilized with 0.5% Triton
X-100 in PBS for 5 min at 4C. Cells were washed with PBST and incubated
with a mouse HA antibody and a rabbit primary antibody for another protein
of interest together for 1 hr at 37C in humidified chamber. Cells were washed
with PBST, incubated with proximity ligation assay probes for another hour,
and then subsequently incubated with ligation and amplification buffer accord-
ing to the vendor’s recommendations. Coverslips were then mounted on glass
slides using mounting media containing DAPI (Vectashield) and foci imaged
and quantified using a florescence microscope.
Generation of KIAA0157 Floxed Mice and Murine Embryonic
Fibroblasts
Gene targeting of the murine KIAA0157 locus was performed by inGenious
Targeting Laboratories. A targeting construct including a neomycin resistance
cassette (neo) (flanked by FLP site) and a 2.2 kb fragment containing exons 6 to
7, each flanked by loxP sites, was generated. This construct was electropo-
rated into C57BL/6N embryonic stem (ES) cells. C57BL/6N ES cells that had
undergone homologous recombination were then microinjected into Balb/c
blastocysts. The resulting chimeras that had high percentage black coat color
were mated to wild-type C57BL/6N mice to generate F1 heterozygous mice.
The F1 heterozygous mice were mated to ACTFLPe(B6.Cg) transgenic mice
(The Jackson Laboratory) to generate F2 KIAA+/FL heterozygous mice. The
F2 generated F2 KIAA+/FL heterozygous mice were mated to CMV-cre
(B6.C) transgenic mice (The Jackson Laboratory) to generate F2 KIAA+/ het-
erozygous mice. The F2 KIAA+/ heterozygous mice were mated each other
and viable KIAA/ offspring were generated. Primers used for PCR genotyp-
ing were as follows: KIAA0157+/+: forward primer 50-TTTCCAGCTGGTTCA
TAGGG-30 and reverse primer 50-GAAGGACGGTCAGCCTGTAG-30. For
KIAA0157/, a 514 bp band was generated using forward primer 50-TGA
TAGTGAGCCATTATGTGGGTG-30 and reverse primer 50-GAAGGACGGT
CAGCCTGTAG-30. Primary MEFs were generated from matings of KIAA+/
heterozygous mice and immortalized by infection with shRNA against
p19ARF lentivirus. All experiments involving mice were approved by the Uni-
versity of Pennsylvania IACUC committee and performed in accordance with
these standards.
SHMT Activity Assay
SHMT activity was analyzed by a radio assay method (Scheer et al., 2005),
where tetrahydrofolate (THF) accelerates the exchange of the pro-2S proton
from 2-3H glycine to water. The counts exchanged from glycine to water are
proportional to the enzymatic activity. In order to purify commercially available
2-3H glycine, a fraction of crude 2-3H glycine was acidified using 1MHCL and
passed through a column containing AG-50 X8 ion-exchange resin. After
extensive washes, purified glycine was eluted using 1 M NH4OH. The eluted
glycine was dried under nitrogen spray and dissolved in 20 mM phosphate
buffer to 1 million CPM/ml. For assaying SHMT activity, protein-A beads
were incubated with purified SHMT2, Abraxas, KIAA0157, and IgG antibodies.
These beads were used to pull respective proteins from HeLa or 293T cell
lysates. Equal amounts of SHMT2 (as analyzed by immunoblot) attached to
the beads were incubated for 1 hr in 400 ml of assay buffer containing
20 mM phosphate buffer (pH 7.3), 1 mM glycine, 10 mM 2-mercaptoethanol,
and 4 ml of purified 2-3H at 37C. Reactions were started by adding 1 mM
THF and stopped by adding cold 50 mM HCl. The mixture was then loaded
on the top of an AG-50 X8 matrix column and washed with 2 ml of 50 mM
HCl. The exchanged amount of 3H in collected washes was analyzed in scin-
tillation counter and activity data were normalized by control beads activity.
Purification of DUBComplexes and IFNAR1- and IFNAR2-Interacting
Proteins
HeLa S3 cells expressing FLAG-HA-KIAA0157 and FLAG-HA-Abraxas pro-
teins were grown in suspension culture in spinner flasks. Purifications were
performed according to Shao et al. (Shao et al., 2009b). FLAG beads were
washed, eluted by FLAG-peptide elution and loaded on SDS-PAGE for visual-
izing protein bands upon Coomassie staining.
IFNAR1 purifications were performed in 293T cells that were transiently
transfected with FLAG-IFNAR1Y466F internalization deficient mutant of IFNAR1
(Kumar et al., 2007) and HA-IFNAR2 (a kind gift of J. Krolewski). Then 48 hr
after transfection, cells were washed, treated with IFNa (500 U/ml for 2 min),
and harvested. Cells were resuspended in ice-cold hypotonic buffer (10 mM
Tris-HCl [pH 7.4], 7.5 mM KCl, 1.5 mM MgCl2, 5 mM b-mercaptoethanol,
and 0.5 mM PMSF). After 15 min incubation on ice, cells were disrupted with
20 strokes in Dounce homogenizer and the extracts were centrifuged to sepa-
rate the nuclear and cytoplasmic fractions. The cytoplasmic fraction was sub-
jected to overnight dialysis in NETENG-200 buffer (200 mM NaCl, 0.5 mM
EDTA, 20mM Tris-HCl [pH 7.4], 0.1%Nonidet P-40, 1.5 mMMgCl2, 10% glyc-
erol, 5 mM b-mercaptoethanol, and 0.5 mM PMSF) with gentle agitation. After
dialysis, the cytoplasmic fraction was clarified by centrifugation (30,000 3 g
for 30 min at 4C) and used for immunoprecipitation with M2-agarose (Sigma-
Aldrich; 10 ml of packed agarose beads per 1 ml of extract). After thorough
washes, bound proteins were eluted with 33 FLAG peptide, reprecipitated
with immobilized HA antibody, washed, eluted with Laemmli buffer, and sepa-
rated on 12%–20%SDS-PAGE.Wide gel segments corresponding to differentCmolecular weight rangewere cut and analyzed bymass spectrometry (Harvard
Proteomics facility).
Viral Infections
MEFs were treated with low doses of IFN (1–4 IU/ml) for 1 hr and then washed
extensively prior to adding media lacking IFN. Following an 18 hr recovery
period, VSV (0.1 MOI; Indiana serotype, propagated in HeLa cells) was used
to infect MEFs for 1 hr. After removing the virus inoculums, cells were then
fed with fresh medium and incubated for 24 hr. Culture supernatant was har-
vested and viral titer was determined in HeLa cells overlaid with methylcellu-
lose as described elsewhere (Zheng et al., 2011). The expression of VSV-M
protein in cell lysates was analyzed by immunoblot.
Cell Viability
ImmortalizedMEFswere seeded at low confluency (30%) and treated with or
without 200 U/ml of mouse-IFN-b for 48 hr. Cells were harvested and cell
viability was estimated using Trypan blue exclusion assay. For LPS treatment,
cells at higher confluency (80%) were treated with or without 10 ng/ml LPS
and 10 mg/ml cycloheximide (CHX). Cells treated only with CHX were used
to normalize the cell viability after LPS treatment.
Caspase-1 Processing
A population of bone marrow cells was isolated from wild-type and KIAA0157
null mice and cells were plated in L929 conditioned media for macrophage
differentiation. After 1 week, macrophages were treated with or without
200 ng/ml of LPS for 12 hr. LPS-stimulated cells were treated with or without
2 mM ATP 30 min before cell harvesting. Cells were lysed in NETN150 buffer
and an equal amount of protein was loaded on a 4%–12% PAGE gel. A cas-
pase-1 antibody that recognizes procaspase-1 and processed caspase-1
(p20, p10) was used for immunoblot to analyze the extent of caspase
processing.
In Vitro DUB Assay
BRISC complex containing active BRCC36-WT or catalytically inactive
BRCC36-QSQwas purified from Sf9 cells as described before (Patterson-For-
tin et al., 2010). 293T cells transiently expressing FLAG-IFNAR1 were treated
with aIFN for 2 hr and lysed. Recombinant R1 substrate was then immunopuri-
fied using FLAGM2 agarose beads and eluted with FLAG peptide. The R1 sub-
strate was incubated with active or inactive BRISC protein in deubiquitination
buffer (Patterson-Fortin et al., 2010) for 2 hr. The reaction was stopped by
adding 2X SDS loading buffer and loaded on 4%–12% SDS PAGE gel. The
proteins were blotted and K63-ubiqutination status of R1 was detected using
specific antibodies.
Animals and LPS Toxicity
The Institutional Animal Care and Use Committee (IACUC) of the University of
Pennsylvania approved all animal procedures of disease modeling, blood
collection, euthanasia, and tissue harvesting (protocols 804095, 803995,
and 803170). Eight- to ten-week-old female C57BL/6 littermatemice, including
wild-type (Kiaa0157+/+) mice and Kiaa0157/ mice (generated during this
study) were used in all experiments. For the generalized inflammation model,
mice were treated with LPS (10.5 mg/kg, intraperitoneal injection) and sacri-
ficed when they became moribund and displayed the loss of righting reflex,
loss of >20% of body weight, and nonresponsiveness to footpad compression
as previously described (Karaghiosoff et al., 2003). Lung tissues from LPS-
treated wild-type and KIAA0157 null mice were harvested at 4–5 days of injec-
tion. Lungs were inflated and fixed with 4% paraformaldehyde, dehydrated,
and embedded in paraffin. Tissue were further sectioned and stained with
hematoxylin and eosin. Levels of IL1b protein in blood plasma were analyzed
using ELISA kit (eBioscience).
Flow Cytometry
Blood was stained with biotinylated antibodies against mouse IFNAR1 or
biotinylated isotype control antibodies. Red blood cells (RBCs) were lysed us-
ing the RBC lysis buffer (155mMNH4Cl, 12mMKHCO3, and 0.1mMEDTA) for
5 min and washed with PBS. Cells were then washed and stained withell Reports 5, 180–193, October 17, 2013 ª2013 The Authors 191
phycoerythrin conjugated streptavidin. All cells were analyzed using
LSRFortessa flow cytometer (BD Biosciences).
Bone-marrow-derived macrophages (BMM) were harvested by enzyme-
free cell detachment solution (Invitrogen) and used for flow cytometry analysis
of surface IFNAR1. BMM stained with viability dye (fixable eFluor 506,
eBioscience) were washed and stained with a cocktail containing APC-labeled
antibodies against F4/80, PerCP-Cy.5.5-labeled antibodies against CD11b
(BioLegend), biotinylated antibodies against mouse IFNAR1, or biotinylated
isotype control antibodies (MOPC-21, ‘‘BioLegend’’). Cells were then washed
and stained with phycoerythrin-conjugated streptavidin. All cells were
analyzed using LSRFortessa flow cytometer (BD Biosciences). Only viable
nonaggregated CD11b/F480 double-positive cells were analyzed for IFNAR1
surface expression (nearly 98% of cells were double positive and viable).
Real-Time PCR
Cells or tissues were flash-frozen and pulverized in liquid nitrogen, homoge-
nized in TRIzol reagent, and extracted with chloroform. Reverse transcription
was carried out using Revertaid first-strand cDNA synthesis kit (K1621,
Thermo Scientific) and the complementary DNA was used for real-time quan-
titative PCR analysis of expression of cytokines and b-actin mRNA using the
following primers: IFNb (forward: 50-AGCTCCAAGAAAGGACGAACAT-30,
reverse: 50-GCCCTGTAGGTGAGGTTGATCT-30), IFNa4 (forward: 50-CCT
GTGTGATGCAGGAACC-30, reverse: 50-TCACCTCCCAGGCACAGA-30), IL1b
(forward: 50-CAACCAACAAGTGATATTCTCCATG-30, reverse: 50-GATCCA
CACTCTCCAGCTGCA-30), b-actin (forward: 50-AGAGGGAAATCGTGCGT
GAC-30, reverse: 50-CAATAGTGATGACCTGGCCGT-30 ) using an Applied Bio-
systems 7500 fast real-time PCR system. All analyses were carried out in
triplicate.
IFNAR1 Internalization Assays
Internalization of endogenous IFNAR1 was determined using a high-
throughput fluorescence-based method described in detail elsewhere (Kumar
et al., 2007, 2008). Briefly, cells in 60mmdishes were transfected with the indi-
cated constructs or induced with tetracycline and plated equally on 24-well
poly-D-lysine plates (Becton Dickinson). Cells were starved in DMEM lacking
FBS and were either treated with starvation media supplemented with IFNa2a
for the indicated time periods or were kept on ice and not exposed to the
IFNa2a supplemented media (time point 0). The cells were washed, blocked,
and incubated with the anti-iFNAR1 AA3 antibody (Goldman et al., 1999) for
human IFNAR1 or mIFNAR1 antibody for mouse receptor. The primary anti-
bodies were then removed and the cells were washed extensively before add-
ing a goat anti mouse IgG H + L horseradish-peroxidase-conjugated antibody.
Following another series of washes, the cells were incubated with AmplexRed
Ultra Reagent 10-acetyl-3,7-dihydroxyphenoxazine (Molecular Probes). Ali-
quots were transferred to a black 96-well plate (NUNC) and fluorescence
was measured by reading with a Beckman Coulter DTX 880Multimode Detec-
tor plate reader using a 530 nm filter for excitation and a 590 nm filter for emis-
sion. Results were calculated using the following formula: % Internalized =
100  [(Vs  Vb) 3 tn/(Vs  Vb) 3 t0]3 100, where Vs is the value of samples,
Vb is the value of background (mock transfected or probed with irrelevant anti-
body), tn is time point n, and t0 is time point 0.
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